tbuckley/cabot-search huggingface dataset:
Call to Action: Maternal Health and Saving Mothers: A Policy Statement From the American Heart Association
Authors: Laxmi S. Mehta, Garima Sharma, Andreea A. Creanga, Afshan B. Hameed, Lisa M. Hollier, Janay C. Johnson, Lisa Leffert, Louise D. McCullough, Mahasin S. Mujahid, Karol Watson, Courtney J. White
Journal: Circulation (2021)

The United States has the highest maternal mortality rates among developed countries, and cardiovascular disease is the leading cause. Therefore, the American Heart Association has a unique role in advocating for efforts to improve maternal health and to enhance access to and delivery of care before, during, and after pregnancy. Several initiatives have shaped the time course of major milestones in advancing maternal and reproductive health equity in the United States. There have been significant strides in improving the timeliness of data reporting in maternal mortality surveillance and epidemiological programs in maternal and child health, yet more policy reforms are necessary. To make a sustainable and systemic impact on maternal health, further efforts are necessary at the societal, institutional, stakeholder, and regulatory levels to address the racial and ethnic disparities in maternal health, to effectively reduce inequities in care, and to mitigate maternal morbidity and mortality. In alignment with American Heart Association's mission "to be a relentless force for longer, healthier lives," this policy statement outlines the inequities that influence disparities in maternal outcomes and current policy approaches to improving maternal health and suggests additional potentially impactful actions to improve maternal outcomes and ultimately save mothers' lives.
Quantifying rapid bacterial evolution and transmission within the mouse intestine
Authors: Kimberly S. Vasquez, Lisa Willis, Nate J. Cira, Katharine M. Ng, Miguel F. Pedro, Andrés Aranda-Díaz, Manohary Rajendram, Feiqiao Brian Yu, Steven K. Higginbottom, Norma Neff, Gavin Sherlock, Karina B. Xavier, Stephen R. Quake, Justin L. Sonnenburg, Benjamin H. Good, Kerwyn Casey Huang
Journal: Cell Host & Microbe (2021)
Neuropsychopharmacology and the Affective Disorders
Authors: Joseph J. Schildkraut
Journal: New England Journal of Medicine (1969)

AmphetamineThe acute stimulant and euphoriant effects of amphetamine in man are well established,173 but this drug is of little value in the treatment of the major depressive disorders. Amphetamine inhibits the neuronal uptake of norepinephrine in brain; increased levels of normetanephrine-3H and decreased levels of tritiated deaminated catechol metabolites are found in brain after intraventricular injection of norepinephrine-3H.147,148, 174 , 175 Amphetamine also appears to release norepinephrine and dopamine from neurons.148, 176 Because of these and similar findings, it has been suggested that amphetamine might exert its central effects indirectly by releasing catecholamines and preventing the inactivation of these monoamines at . . .
Myeloid‐derived suppressor cells in obesity‐associated periodontal disease: A conceptual model
Authors: Kyu Hwan Kwack, Victoria Maglaras, Ramkumar Thiyagarajan, Lixia Zhang, Keith L. Kirkwood
Journal: Periodontology 2000 (2021)

Abstract Periodontitis is a common chronic inflammatory disease characterized by destruction of the supporting structures of the teeth. Severe periodontitis is highly prevalent—affecting 10%‐15% of adults—and carries several negative comorbidities, thus reducing quality of life. Although a clear relationship exists between severity of obesity and incidence of periodontal disease, the biologic mechanisms that support this link are incompletely understood. In this conceptual appraisal, a new “two‐hit” model is presented to explain obesity‐exacerbated periodontal bone loss. This proposed model recognizes a previously unappreciated aspect of myeloid‐derived suppressor cell population expansion, differentiation, and activity that can participate directly in periodontal bone loss, providing new mechanistic and translational perspectives.
抗IFN-αモノクローナル抗体,sifalimumabを評価する第1b相臨床試験は皮膚筋炎および多発性筋炎患者の血液においてI型IFNシグネチャーの標的中和を示す
Authors: Higgs Brandon W, Zhu Wei, Morehouse Chris, White Wendy I, Brohawn Philip, Guo Xiang, Rebelatto Marlon, LE Chenxiong, Amato Anthony, Fiorentino David, Greenberg Steven A, Drappa Jorn, Richman Laura, Greth Warren, Jallal Bahija, Yao Yihong
Journal: Annals of the Rheumatic Diseases (2014)
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Authors: Alexander G. Mathioudakis, Fekri Abroug, Alvar Agusti, Sachin Ananth, Per Bakke, Konstantinos Bartziokas, Bianca Beghe, Andras Bikov, Thomas Bradbury, Guy Brusselle, Cordula Cadus, Courtney Coleman, Marco Contoli, Alexandru Corlateanu, Olga Corlateanu, Gerard J. Criner, Balazs Csoma, Alexander Emelyanov, Rosa Faner, Gustavo Fernandez Romero, Zeineb Hammouda, Peter Horváth, Arturo Huerta Garcia, Michael Jacobs, Christine Jenkins, Guy Joos, Olga Kharevich, Konstantinos Kostikas, Elena Lapteva, Zsofia Lazar, Joerg D. Leuppi, Carol Liddle, John Linnell, Alejandra López-Giraldo, Vanessa M. McDonald, Rune Nielsen, Alberto Papi, Isabel Saraiva, Galina Sergeeva, Agni Sioutkou, Pradeesh Sivapalan, Elizabeth Stovold, Hao Wang, Fuqiang Wen, Janelle Yorke, Paula R. Williamson, Jørgen Vestbo, Jens-Ulrik Jensen
Journal: European Respiratory Journal (2021)

Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients. We have developed a core outcome set, a consensus-based minimum set of important outcomes that we recommend are evaluated in all future clinical trials on exacerbations management, to improve their quality and comparability. COPD exacerbations outcomes were identified through methodological systematic reviews and qualitative interviews with 86 patients from 11 countries globally. The most critical outcomes were prioritised for inclusion in the core outcome set through a two-round Delphi survey completed by 1063 participants (256 patients, 488 health professionals and 319 clinical academics) from 88 countries in five continents. Two global, multi-stakeholder, virtual consensus meetings were conducted to 1) finalise the core outcome set and 2) prioritise a single measurement instrument to be used for evaluating each of the prioritised outcomes. Consensus was informed by rigorous methodological systematic reviews. The views of patients with COPD were accounted for at all stages of the project. Survival, treatment success, breathlessness, quality of life, activities of daily living, the need for a higher level of care, arterial blood gases, disease progression, future exacerbations and hospital admissions, treatment safety and adherence were all included in the core outcome set. Focused methodological research was recommended to further validate and optimise some of the selected measurement instruments. The panel did not consider the prioritised set of outcomes and associated measurement instruments to be burdensome for patients and health professionals to use.
Enabling rational gut microbiome manipulations by understanding gut ecology through experimentally-evidenced in silico models
Authors: Juan P. Molina Ortiz, Dale D. McClure, Erin R. Shanahan, Fariba Dehghani, Andrew J. Holmes, Mark N. Read
Journal: Gut Microbes (2021)

The gut microbiome has emerged as a contributing factor in non-communicable disease, rendering it a target of health-promoting interventions. Yet current understanding of the host-microbiome dynamic is insufficient to predict the variation in intervention outcomes across individuals. We explore the mechanisms that underpin the gut bacterial ecosystem and highlight how a more complete understanding of this ecology will enable improved intervention outcomes. This ecology varies within the gut over space and time. Interventions disrupt these processes, with cascading consequences throughout the ecosystem. In vivo studies cannot isolate and probe these processes at the required spatiotemporal resolutions, and in vitro studies lack the representative complexity required. However, we highlight that, together, both approaches can inform in silico models that integrate cellular-level dynamics, can extrapolate to explain bacterial community outcomes, permit experimentation and observation over ecological processes at high spatiotemporal resolution, and can serve as predictive platforms on which to prototype interventions. Thus, it is a concerted integration of these techniques that will enable rational targeted manipulations of the gut ecosystem.
Call for emergency action to limit global temperature increases, restore biodiversity and protect health
Authors: Lukoye Atwoli, Abdullah H Baqui, Thomas Benfield, Raffaella Bosurgi, Fiona Godlee, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Carlos Augusto Monteiro, Ian Norman, Kirsten Patrick, Nigel Praities, Marcel GM Olde Rikkert, Eric J Rubin, Peush Sahni, Richard Smith, Nicholas J Talley, Sue Turale, Damián Vázquez
Journal: British Journal of Sports Medicine (2021)

> Wealthy nations must do much more, much faster.

The United Nations General Assembly in September 2021 will bring countries together at a critical time for marshalling collective action to tackle the global environmental crisis. They will meet again at the biodiversity summit in Kunming, China, and the climate conference (Conference of the Parties (COP)26) in Glasgow, UK. Ahead of these pivotal meetings, we—the editors of health journals worldwide—call for urgent action to keep average global temperature increases below 1.5°C, halt the destruction of nature and protect health.

Health is already being harmed by global temperature increases and the destruction of the natural world, a state of affairs health professionals have been bringing attention to for decades.1 The science is unequivocal; a global increase of 1.5°C above the preindustrial average and the continued loss of biodiversity risk catastrophic harm to health that will be impossible to reverse.2 3 Despite the world’s necessary preoccupation with COVID-19, we cannot wait for the pandemic to pass to rapidly reduce emissions.

Reflecting the severity of the moment, this editorial appears in health journals across the world. We are united in recognising that only fundamental and equitable changes to societies will reverse our current trajectory.

The risks to health of increases above 1.5°C are now well established.2 Indeed, no temperature rise is ‘safe’. In the past 20 years, heat-related mortality among people aged over 65 has increased by more than 50%.4 Higher temperatures have brought increased dehydration and renal function loss, dermatological malignancies, tropical infections, adverse mental health outcomes, pregnancy complications, allergies, and cardiovascular and pulmonary morbidity and mortality.5 6 Harms disproportionately affect the most vulnerable, including children, older populations, ethnic minorities, poorer communities and those with underlying health problems.2 4

Global heating is also contributing to the decline in …
Phosphoproteomic Profiling Reveals Metabolic Factors Facilitating Leukemia-Stroma Crosstalk in Acute Myeloid Leukemia
Authors: Liliana H Mochmann, Denise Treue, Michael Bockmayr, Eva Kristin Von Der Heide, Patricia Silva, Konstandina Isaakidis, Caroline Busch, Hifza Siddiq, Martin Neumann, Lars Fransecky, Frederick Klauschen, Claudia D. Baldus
Journal: Blood (2017)
Beyond stereotypes: Prejudice as an important missing force explaining group disparities
Authors: Iniobong Essien, Marleen Stelter, Anette Rohmann, Juliane Degner
Journal: Behavioral and Brain Sciences (2022)

Abstract We comment on Cesario's assertion that social psychological intergroup research focuses solely on stereotypes , neglecting actual differences between groups to explain group disparities. This reasoning, however, misses yet another explaining force: In addition to stereotypes, ample laboratory and field research documents relationships between group disparities, discrimination, and prejudice , which cannot be explained by people's accurate judgments of real-world group differences.
Foundational Considerations for Artificial Intelligence Using Ophthalmic Images
Authors: Michael D. Abràmoff, Brad Cunningham, Bakul Patel, Malvina B. Eydelman, Theodore Leng, Taiji Sakamoto, Barbara Blodi, S. Marlene Grenon, Risa M. Wolf, Arjun K. Manrai, Justin M. Ko, Michael F. Chiang, Danton Char, Michael Abramoff, Mark Blumenkranz, Emily Chew, Michael Chiang, Malvina Eydelman, David Myung, Joel S. Schuman, Carol Shields, Michael D. Abràmoff, Malvina B. Eydelman, Brad Cunningham, Bakul Patel, Karen A. Goldman, Danton Char, Taiji Sakamoto, Barbara Blodi, Risa Wolf, Jean--Louis Gassee, Theodore Leng, Dan Roman, Sally Satel, Donald Fong, David Rhew, Henry Wei, Michael Willingham, Michael Chiang, Mark Blumenkranz
Journal: Ophthalmology (2021)
The Harmful Effects of Policing—From the Neighborhood to the Hospital
Authors: Nia Heard-Garris, Tiffani J. Johnson, Rachel Hardeman
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials
Authors: Jun Yin, Mohamed E Salem, Jesse G Dixon, Zhaohui Jin, Romain Cohen, Aimery DeGramont, Eric Van Cutsem, Julien Taieb, Steven R Alberts, Norman Wolmark, Hans-Joachim Schmoll, Leonard B Saltz, Thomas J George, Richard R M Goldberg, Rachel Kerr, Sara Lonardi, Takayuki Yoshino, Greg Yothers, Axel Grothey, Thierry Andre, Qian Shi
Journal: JNCI Journal of the National Cancer Institute (2021)

Abstract Background Disease-free survival (DFS) with a 3-year median follow-up (3-year DFS) was validated as a surrogate for overall survival (OS) with a 5-year median follow-up (5-year OS) in adjuvant chemotherapy colon cancer (CC) trials. Recent data show further improvements in OS and survival after recurrence in patients who received adjuvant FOLFOX. Hence, reevaluation of the association between DFS and OS and determination of the optimal follow-up duration of OS to aid its utility in future adjuvant trials are needed. Methods Individual patient data from 9 randomized studies conducted between 1998 and 2009 were included; 3 trials tested biologics. Trial-level surrogacy examining the correlation of treatment effect estimates of 3-year DFS with 5 to 6.5-year OS was evaluated using both linear regression (RWLS2) and Copula bivariate (RCopula2) models and reported with 95% confidence intervals (CIs). For R2, a value closer to 1 indicates a stronger correlation. Results Data from a total of 18 396 patients were analyzed (median age = 59 years; 54.0% male), with 54.1% having low-risk tumors (T1-3 and N1), 31.6% KRAS mutated, 12.3% BRAF mutated, and 12.4% microsatellite instability high or deficient mismatch repair tumors. Trial-level correlation between 3-year DFS and 5-year OS remained strong (RWLS2 = 0.82, 95% CI = 0.67 to 0.98; RCopula2 = 0.92, 95% CI = 0.83 to 1.00) and increased as the median follow-up of OS extended. Analyses limited to trials that tested biologics showed consistent results. Conclusions Three-year DFS remains a validated surrogate endpoint for 5-year OS in adjuvant CC trials. The correlation was likely strengthened with 6 years of follow-up for OS.
Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19
Authors: Benjamin Krämer, Rainer Knoll, Lorenzo Bonaguro, Michael ToVinh, Jan Raabe, Rosario Astaburuaga-García, Jonas Schulte-Schrepping, Kim Melanie Kaiser, Gereon J. Rieke, Jenny Bischoff, Malte B. Monin, Christoph Hoffmeister, Stefan Schlabe, Elena De Domenico, Nico Reusch, Kristian Händler, Gary Reynolds, Nils Blüthgen, Gudrun Hack, Claudia Finnemann, Hans D. Nischalke, Christian P. Strassburg, Emily Stephenson, Yapeng Su, Louis Gardner, Dan Yuan, Daniel Chen, Jason Goldman, Philipp Rosenstiel, Susanne V. Schmidt, Eicke Latz, Kevin Hrusovsky, Andrew J. Ball, Joe M. Johnson, Paul-Albert Koenig, Florian I. Schmidt, Muzlifah Haniffa, James R. Heath, Beate M. Kümmerer, Verena Keitel, Björn Jensen, Paula Stubbemann, Florian Kurth, Leif E. Sander, Birgit Sawitzki, Anna C. Aschenbrenner, Joachim L. Schultze, Jacob Nattermann, Janine Altmüller, Angel Angelov, Anna C. Aschenbrenner, Robert Bals, Alexander Bartholomäus, Anke Becker, Matthias Becker, Daniela Bezdan, Michael Bitzer, Conny Blumert, Ezio Bonifacio, Peer Bork, Bunk Boyke, Helmut Blum, Nicolas Casadei, Thomas Clavel, Maria Colome-Tatche, Markus Cornberg, Inti Alberto De La Rosa Velázquez, Andreas Diefenbach, Alexander Dilthey, Nicole Fischer, Konrad Förstner, Sören Franzenburg, Julia-Stefanie Frick, Gisela Gabernet, Julien Gagneur, Tina Ganzenmueller, Marie Gauder, Janina Geißert, Alexander Goesmann, Siri Göpel, Adam Grundhoff, Hajo Grundmann, Torsten Hain, Frank Hanses, Ute Hehr, André Heimbach, Marius Hoeper, Friedemann Horn, Daniel Hübschmann, Michael Hummel, Thomas Iftner, Angelika Iftner, Thomas Illig, Stefan Janssen, Jörn Kalinowski, René Kallies, Birte Kehr, Andreas Keller, Oliver T. Keppler, Sarah Kim-Hellmuth, Christoph Klein, Michael Knop, Oliver Kohlbacher, Karl Köhrer, Jan Korbel, Peter G. Kremsner, Denise Kühnert, Ingo Kurth, Markus Landthaler, Yang Li, Kerstin U. Ludwig, Oliwia Makarewicz, Federico Marini, Manja Marz, Alice C. McHardy, Christian Mertes, Maximilian Münchhoff, Sven Nahnsen, Markus Nöthen, Francine Ntoumi, Peter Nürnberg, Stephan Ossowski, Jörg Overmann, Silke Peter, Klaus Pfeffer, Isabell Pink, Anna R. Poetsch, Ulrike Protzer, Alfred Pühler, Nikolaus Rajewsky, Markus Ralser, Kristin Reiche, Olaf Rieß, Stephan Ripke, Ulisses Nunes da Rocha, Philip Rosenstiel, Antoine-Emmanuel Saliba, Leif Erik Sander, Birgit Sawitzki, Simone Scheithauer, Philipp Schiffer, Jonathan Schmid-Burgk, Wulf Schneider, Eva-Christina Schulte, Joachim L. Schultze, Alexander Sczyrba, Mariam L. Sharaf, Yogesh Singh, Michael Sonnabend, Oliver Stegle, Jens Stoye, Fabian Theis, Thomas Ulas, Janne Vehreschild, Thirumalaisamy P. Velavan, Jörg Vogel, Sonja Volland, Max von Kleist, Andreas Walker, Jörn Walter, Dagmar Wieczorek, Sylke Winkler, John Ziebuhr
Journal: Immunity (2021)
Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide For Programs, Faculty, and Fellows
Authors: Brijen J. Shah, Jane E. Onken, Laura Edgar, Janice H. Jou, Keith L. Obstein, Darrell S. Pardi, Seth Richter, Gautham Reddy, Suzanne Rose, Ronald Szyjkowski, Oren K. Fix
Journal: Hepatology (2021)
Surrounding Greenness and Biological Aging Based on DNA Methylation: A Twin and Family Study in Australia
Authors: Rongbin Xu, Shuai Li, Shanshan Li, Ee Ming Wong, Melissa C. Southey, John L. Hopper, Michael J. Abramson, Yuming Guo
Journal: Environmental Health Perspectives (2021)

BACKGROUND: High surrounding greenness has many health benefits and might contribute to slower biological aging.However, very few studies have evaluated this from the perspective of epigenetics.OBJECTIVES: We aimed to evaluate the association between surrounding greenness and biological aging based on DNA methylation.METHODS: We derived Horvath's DNA methylation age (DNAmAge), Hannum's DNAmAge, PhenoAge, and GrimAge based on DNA methylation measured in peripheral blood samples from 479 Australian women in 130 families.Measures of DNAmAge acceleration (DNAmAgeAC) were derived from the residuals after regressing each DNAmAge metric on chronological age.Greenness was represented by satellite-derived Normalized Difference Vegetation Index (NDVI) and Enhanced Vegetation Index (EVI) metrics within 300-, 500-, 1,000-, and 2,000-m buffers surrounding participant addresses.Greenness-DNAmAgeAC associations were estimated using a within-sibship design fitted by linear mixed effect models, adjusting for familial clustering and important covariates.RESULTS: Greenness metrics were associated with significantly lower DNAmAgeAC based on GrimAge acceleration, suggesting slower biological aging with higher greenness based on both NDVI and EVI in 300-2,000 m buffer areas.For example, each interquartile range increase in NDVI within 1,000 m was associated with a 0.59 (95% CI: 0.18, 1.01)-year decrease in GrimAge acceleration.Greenness was also inversely associated with three of the eight components of GrimAge, specifically, DNA methylation-based surrogates of serum cystatin-C, serum growth differentiation factor 15, and smoking pack years.Associations between greenness and biological aging measured by Horvath's and Hannum's DNAmAgeAC were less consistent, and depended on neighborhood socioeconomic status.No significant associations were estimated for PhenoAge acceleration.DISCUSSION: Higher surrounding greenness was associated with slower biological aging, as indicated by GrimAge age acceleration, in Australian women.Associations were also evident for three individual components of GrimAge, but were inconsistent for other measures of biological aging.Additional studies are needed to confirm our results.
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy
Authors: Elise A. Chong, Cécile Alanio, Jakub Svoboda, Sunita D. Nasta, Daniel J. Landsburg, Simon F. Lacey, Marco Ruella, Siddharth Bhattacharyya, E. John Wherry, Stephen J. Schuster
Journal: Blood (2021)
Practical Application of the Athndataset: Evaluating Uptake of Extended Half-Life Factor Concentrates in Patients with Moderate and Severe Hemophilia
Authors: Stacy E. Croteau, Dunlei Cheng, Alice J. Cohen, Chris E. Holmes, Peter A. Kouides, Leslie J Raffini, Michael Silvey, Courtney Thornburg, Allison P. Wheeler, Ellis J Neufeld
Journal: Blood (2017)